Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences

Provided By PR Newswire

Last update: May 4, 2022

BETHESDA, Md., May 4, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax^® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made on May 10, 2022 at 11:10 a.m., by Dr. Linda Liau at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences.